Why Compass Therapeutics stock collapsed after FDA challenged its cancer-drug approval plan
Compass Therapeutics shares plunged to a two-year low after the FDA recommended another survival trial before a tovecimig filing, creating a high-stakes disagreement over whether strong tumor-response and progression-free survival results are enough to support an approval application in advanced biliary tract cancer.